Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas ; volume:8 ; number:1 ; day:10 ; month:1 ; year:2018 ; pages:1-8 ; date:12.2018
Scientific reports ; 8, Heft 1 (10.1.2018), 1-8, 12.2018

Keyword: Krebs
Onkologie

Creator: Lee, Ting-Fang

Contributor: Tseng, Yu-Chi
Nguyen, Phung Anh
Li, Yu-Chuan
Ho, Chao-Chi
Wu, Cheng-Wen
SpringerLink (Online service)

DOI: 10.1038/s41598-017-18527-z

URN: urn:nbn:de:1111-201804043550

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:45 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lee, Ting-Fang
Tseng, Yu-Chi
Nguyen, Phung Anh
Li, Yu-Chuan
Ho, Chao-Chi
Wu, Cheng-Wen
SpringerLink (Online service)

Other Objects (12)

Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Graffiti | Streetart

TKi | TKi

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Graffiti | Streetart

TKi

Graffiti | Streetart

TKI

Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Graffiti | Streetart

TKi | TKi

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Graffiti | Streetart

TKi

Graffiti | Streetart

TKI

Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Graffiti | Streetart

TKi | TKi

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Graffiti | Streetart

TKi

Graffiti | Streetart

TKI

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

TKi | TKi

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

TKi

TKI

Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

TKi | TKi

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

TKi

TKI

Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

TKi | TKi

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

TKi

TKI

Related objects

Reset password